Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Asia Pharmaceutics 2019

About us

Pharmaceutical Conferences team cordially invites participants from all over the world to attend "Asia Pacific Pharmaceutics and Drug Delivery System" (Asian Pharmaceutica 2019) slated on October 16-17, 2019 at Singapore. This Pharmaceutics Conference includes a wide range of Keynote presentations, Oral talks, Poster presentations, Symposia, Workshops, Exhibitions, and Career development programs.

Asia Pacific Pharmaceutics and Drug Delivery System is one of the well-established conferences among Pharmaceutical Conferences organized by Conference Series

Asian Pharmaceutica 2019 covers various aspects of Bio-Pharmaceutics, Pharmaceutical Chemistry, Drug Targeting and Design, Pharmacokinetics and Pharmacodynamics in Drugs, Pharmaceutical Formulation, Pharmaceutical Manufacturing, Pharmaceutical Nanotechnology, Novel Drug Delivery Systems, Smart Drug Delivery Systems, Nanomedicine and Biomedical Applications, Biomaterials in Drug Delivery, Vaccine Drug Delivery Systems, Medical Devices for Drug Delivery, Biologics & Biosimilars, Pharmaceutical Analysis, Pharmaceutical Process Validation, Pharmaceutical Packaging, Clinical Trials and Clinical Research, Pharmacogenetics and Genomics, Regulatory Affairs and Intellectual Property Rights, Industrial and Physical Pharmacy, Clinical and Hospital Pharmacy, Pharmacovigilence and Drug Safety, Pharmacy Education and Practice

2019 Highlights:

  • 200+ Participation (70% Industry: 30% Academia)
  • 9+ Keynote Speakers
  • 30+ Plenary Speakers
  • 3+ Exhibitors
  • 14 Innovative Educational Sessions
  • B2B Meetings

Why you should attend?

  • Access to senior-level executives from leading international pharmaceutical & biotechnology companies
  • Exposure to new and exciting companies ready for partnerships and licensing opportunities in the U.S., Europe and Asia
  • Tremendous networking opportunities to meet numerous U.S., European, Japanese and Asian biotech and pharmaceutical companies in one place at one time
  • Use of state-of-the-art partnering technology
  • Targeted partner selections through proprietary screening process
  • Get to the heart of why formulation and delivery strategies fail. Dissect the challenges before looking for concrete solutions.
  • Discover how advances in the sector are impacting both large and small molecule drugs.
  • Explore tried and tested routes to improve bioavailability.
  • Understand how to develop the right formulation and delivery strategy with a strong scientific, clinical and commercial mind set.
  • Discover the latest innovations in drug delivery devices.
  • Be inspired by innovative case studies and realize the potential impact on your formulation or delivery processes.
  • Engage in the exciting event format, with round tables, panels, showcases, speed networking and multiple conference tracks.
  • Share experiences, insights and strategies in interactive peer to peer round tables.
  • Hear more perspectives in one place – from large medium and small organizations from pharma, biotech and academia.
  • Discover how scientific formulation advancements are being implemented in practice.

Who Should Attend

  • Directors, CEO’s of Organizations
  • Business Development Managers
  • Chief Scientific Officers
  • R&D Researchers from Biosimilar and Biologics Industries
  • Professors, Associate Professors, Assistant Professors
  • PhD Scholars
  • Patent Attorneys
  • Intellectual Property Attorneys
  • Investment Analysts
  • Association, Association presidents and professionals
  • Drug development and discovery companies
  • Formulation and Pharma Manufacturing companies
  • Medical technology companies
  • Universities and institutes
  • Intellectual property and legal organizations
  • Investors and financial services providers
  • Bio-clusters and incubators
  • Government and public support agencies
  • Cosmetic companies
  • Generic drugs and Biosimilars

Market Analysis

Pharmaceutics & Drug Delivery Market Research:

Pharmaceuticals are one of the world's most profitable industries. During the last 30 years, the industry has spent billions of dollars on research and reaped billions in return. In 2008 alone, the pharmaceutical industry sold $773 billion in products worldwide-a number that has consistently grown for the past 8 years and is projected to increase again by 2.5 to 3.5 percent in 2018.

*Source: IMS Health

The Market report of most of the pharmaceutical companies shows their R&D investments majorly in the following areas, namely:

  • Advanced Drug Delivery Systems
  • Antibiotics
  • Excipients in Pharmaceuticals
  • Ophthalmic Therapeutic Drugs
  • Skin Disease Treatment
  • Vaccine Technologies
  • Breakthrough Therapies

Advanced Drug Delivery Systems:

  • The global advanced drug delivery market should grow from roughly $178.8 billion in 2015 to nearly $227.3 billion by 2020, with a compound annual growth rate (CAGR) of 4.9%.
  • The North American market should grow from nearly $75.7 billion in 2015 to $93.4 billion by 2020, a CAGR of 4.3%.
  • The European market should grow from roughly $57.3 billion in 2015 to nearly $72.1 billion by 2020, a CAGR of 4.7%.

*Source: BCC Research

Antibiotics:

  • The global systemic antibiotics market should reach nearly $44.7 billion in 2020 from nearly $40.6 billion in 2015 at a compound annual growth rate (CAGR) of 2.0% from 2015 to 2020.
  • The beta-lactams market should reach over $22.0 billion by 2020 from over $20.6 billion in 2015, a CAGR of 1.3% from 2015 to 2020.
  • The other antibiotic classes market should reach over $10.6 billion in 2020 from nearly $8.3 billion in 2015, a CAGR of 5.0% from 2015 to 2002.

 

*Source: BCC Research

Excipients in Pharmaceuticals:

  • The global excipients market should reach nearly $6.9 billion by 2020 from over $6.2 billion in 2015, a compound annual growth rate (CAGR) of 1.9% from 2015 to 2020.
  • The organic excipients market should reach $6.3 billion by 2020 from nearly $5.8 billion in 2015, a CAGR of 1.7% from 2015 to 2020.
  • The inorganic excipients market should reach $433.7 million by 2020 from $351.9 million in 2015, a CAGR of 4.3% from 2015 to 2020.

*Source: BCC Research

Ophthalmic Therapeutic Drugs:

  • The global ophthalmic therapeutic drug market was valued at $12.3 billion in 2014. This market is expected to reach $19 billion by 2019, with a compound annual growth rate (CAGR) of 9.1% from 2014 to 2019.
  • The global age-related macular degeneration (AMD) market is expected to grow to nearly $7.9 billion by 2019 from nearly $5.4 billion in 2014, a CAGR of 7.8% from 2014 to 2019.
  • The global glaucoma therapeutic market generated revenue of $3.8 billion in 2014, and by 2019 this segment is expected to generate $6.4 billion, with a CAGR of 11.1% from 2014 to 2019.

*Source: BCC Research

Skin Disease Treatment:

  • The global market for skin disease treatment technologies reached $16.4 billion in 2014 and $17.1 billion in 2015. The market should reach $20.4 billion in 2020, demonstrating a compound annual growth rate (CAGR) of 3.6% from 2015 to 2020.
  • The U.S market for skin disease treatment dominates the global market throughout the period, and totaled $7.3 billion in 2014. The market should reach $7.5 billion in 2015 and $8.6 billion in 2020 at a CAGR of 2.6% from 2015 to 2020.
  • BRIC (Brazil, Russia, India, and China) is the fastest growing region of the global dermatology market with a CAGR of 6% from 2015 to 2020. The market totaled $3.5 billion in 2015 and should reach more than $4.6 billion by 2020.

*Source: BCC Research

Vaccine Technologies:

  • The global market for vaccine technologies reached $33.3 billion in 2016 and should reach $45.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 6.3% from 2016 to 2021.
  • Human vaccines as a segment of this market reached $27.2 billion in 2016 and should reach nearly $37.5 billion by 2021, growing at a CAGR of 6.6% from 2016 to 2021.
  • Animal vaccines as a segment of this market reached nearly $6.1 billion in 2016 and should reach $7.7 billion by 2021, growing at a CAGR of 4.9% from 2016 to 2021.

*Source: BCC Research

Breakthrough Therapies:

  • The global market for breakthrough therapy designation (BTD) drugs should reach $99.2 billion by 2022 from $48.8 billion in 2017 at a compound annual growth rate (CAGR) of 15.2%, from 2017 to 2022.
  • The cancer therapy segment of the breakthrough therapy designation drugs industry is the largest market. The market is expected to grow from $19.6 billion in 2017 to $58.6 billion in 2022 at a CAGR of 24.5% for the period 2017-2022.
  • The CNS and neurology therapy segment of the breakthrough therapy designation drugs industry is expected to grow from $956 million in 2017 to $8.4 billion in 2022 at a CAGR of 54.3% for the period 2017-2022.

*Source: BCC Research

2018 Pharmaceuticals Research Review:

Pharmaceuticals represented a US$300 bn-a-year market globally as of 2015, the World Health Organization states. The global pharmaceutical market is expected to surpass US$400 bn by 2018, with the ten largest pharmaceutical companies collectively commanding about a third of the market. Companies in the pharmaceutical industry are characterized by their sizeable expenditure on R&D and marketing initiatives in a bid to rake in more revenue. The development of biopharmaceuticals represents a milestone for the industry and personalized therapies carry immense promise in the near future.

Highlights:

  • The global market for cancer vaccines totaled $4.5 billion in 2013 and reached nearly $4.0 billion in 2014. This market is expected to reach $4.3 billion by 2019, registering a compound annual growth rate (CAGR) of 1.3% for the period 2014-2019.
  • The global market for “silent” cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a CAGR of 8.5% from 2014 to 2019.
  • The global market for incretin-based therapeutics was valued at nearly $11.8 billion in 2013 and $12.7 billion in 2014. This market is expected to reach $22.8 billion by 2019, with a CAGR of 12.4% from 2014 to 2019.

Cancer Vaccines: Technologies and Global Markets:

The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. Extensive promotion and marketing strategies and favorable government support are likely to boost market growth.

The global market for cancer vaccines was valued at nearly $4.2 billion and $4.0 billion in 2014 and 2015, respectively. This market is expected to decline from nearly $3.5 billion in 2016 to $3.4 billion in 2021 at a compound annual growth rate (CAGR) of -0.4% for 2016-2021.

Drug Delivery Companies:

The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. This market is segmented based on route of administration, facility of use, and region.

The drug delivery technology is highly competitive market, comprising of various players. Prominent players in the drug delivery technology market include Johnson & Johnson, Inc. (U.S.), F. Hoffman-La Roche (Switzerland), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), Novartis AG (Switzerland), 3M Company (U.S.), Becton, Dickinson and Company (U.S.), GlaxoSmithKline plc, (U.K.), Sanofi (France), and Antares Pharma, Inc. (U.S.).

Nanotechnology Drug Delivery Market:

The global nanotechnology drug delivery market was valued at US$ 41,062.5 Mn in 2014 and is projected to reach US$ 118,527.2 Mn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023.

Key players having a presence in the global nanotechnology drug delivery market are AbbVie, Inc., Amgen, Inc., Celgene Corporation, Johnson & Johnson, Merck & Co., Inc., and Novartis International AG, among others.

Active Pharmaceutical Ingredient Market:

Transparency Market research states the opportunity in this market will be worth US$219.60 bn by 2023 from US$134.7 bn in 2015. Between the forecast period of 2015 and 2023, the overall market is expected to expand at a CAGR of 6.3%.

Some of the leading companies operating in the global active pharmaceutical ingredient market are Zhejiang Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., Zhejiang NHU Co., Ltd , North China Pharmaceutical Group Corp. (NCPC), Dr.Reddy’s Laboratories Limited, Northeast Pharmaceutical Group Co., Ltd., Aurobindo Pharma Limited, Sandoz (Novartis AG), Zhejiang Hisun Pharmaceutical Co., Ltd. and Zhejiang Huahai Pharmaceuticals Co., Ltd. amongst others. Currently, these players are focusing on partnering with other companies to acquire a new line of products to add value to their portfolio. Furthermore, companies are also anticipated to focus on expanding their capacities to cater to the vast unmet medical needs of the world.

 

Target Audience:

  • Drug Delivery Technology Manufacturers
  • Public and Private Physicians
  • Healthcare Institutions (Medical Data Centers)
  • Research & Clinical Laboratories
  • Distributors and Suppliers of Drug Delivery Technologies
  • Health Insurance Payers
  • Market Research and Consulting Firms

To Collaborate Scientific Professionals around the World

Conference Date October 16-17, 2019

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Past Conference Report

Supported By

Journal of Nanomedicine & Nanotechnology Journal of Pharmaceutics & Drug Delivery Research Journal of Pharmaceutical Sciences & Emerging Drugs Journal of Nanomedicine & Biotherapeutic Discovery

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by